Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) Cost of Revenue (2021 - 2025)

Tarsus Pharmaceuticals (TARS) has 5 years of Cost of Revenue data on record, last reported at $10.9 million in Q4 2025.

  • For Q4 2025, Cost of Revenue rose 121.82% year-over-year to $10.9 million; the TTM value through Dec 2025 reached $30.7 million, up 139.23%, while the annual FY2025 figure was $30.7 million, 139.23% up from the prior year.
  • Cost of Revenue reached $10.9 million in Q4 2025 per TARS's latest filing, up from $8.3 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $10.9 million in Q4 2025 and bottomed at -$24000.0 in Q4 2021.
  • Average Cost of Revenue over 5 years is $2.8 million, with a median of $1.3 million recorded in 2021.
  • The widest YoY moves for Cost of Revenue: up 1766.67% in 2022, down 97.46% in 2022.
  • A 5-year view of Cost of Revenue shows it stood at -$24000.0 in 2021, then soared by 1766.67% to $400000.0 in 2022, then surged by 204.0% to $1.2 million in 2023, then surged by 305.1% to $4.9 million in 2024, then soared by 121.82% to $10.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $10.9 million in Q4 2025, $8.3 million in Q3 2025, and $6.2 million in Q2 2025.